Review the specific labeling changes required by the FDA order and update internal safety documents and signal evaluation for ADZYNMA accordingly.
Consumers must stop taking the product immediately and return remaining capsules to a pharmacy for safe disposal.
Identify and quarantine products from lots 1725204004 and 1725069002; contact patients who received sensors from these lots; report adverse events if any.
Return recalled products to place of purchase for refund or contact Customer Care for return arrangements.
Identify and quarantine all impacted batches of ChloraPrep 2% 1mL and Frepp 2% 1.5mL applicators; return to Becton Dickinson UK Ltd.
Identify affected lots and implement recall procedures as per Health Canada guidelines.
Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.
Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.
